Horizon Pharma PLC (NASDAQ:HZNP) – Research analysts at Jefferies Group lifted their FY2017 earnings estimates for Horizon Pharma PLC in a research report issued on Tuesday. Jefferies Group analyst D. Steinberg now forecasts that the biopharmaceutical company will post earnings of $0.71 per share for the year, up from their prior forecast of $0.69. Jefferies Group currently has a “Buy” rating and a $21.00 target price on the stock. Jefferies Group also issued estimates for Horizon Pharma PLC’s FY2021 earnings at $1.73 EPS.
A number of other analysts also recently commented on HZNP. Mizuho reissued a “neutral” rating and set a $9.00 price objective (down previously from $10.00) on shares of Horizon Pharma PLC in a report on Wednesday, August 9th. Zacks Investment Research raised shares of Horizon Pharma PLC from a “sell” rating to a “hold” rating in a report on Friday, August 11th. BMO Capital Markets reissued an “outperform” rating and set a $18.00 price objective (up previously from $17.00) on shares of Horizon Pharma PLC in a report on Thursday, August 10th. UBS AG set a $16.00 price objective on shares of Horizon Pharma PLC and gave the stock a “buy” rating in a report on Tuesday, August 8th. Finally, Cantor Fitzgerald restated a “buy” rating and set a $17.00 target price on shares of Horizon Pharma PLC in a research report on Tuesday, September 26th. One investment analyst has rated the stock with a sell rating, three have given a hold rating and eleven have issued a buy rating to the company’s stock. The stock currently has an average rating of “Buy” and a consensus target price of $18.42.
ILLEGAL ACTIVITY NOTICE: “FY2017 EPS Estimates for Horizon Pharma PLC (HZNP) Raised by Analyst” was originally posted by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece of content on another publication, it was illegally stolen and republished in violation of U.S. & international copyright & trademark law. The legal version of this piece of content can be accessed at https://www.dispatchtribunal.com/2017/11/12/fy2017-eps-estimates-for-horizon-pharma-plc-hznp-raised-by-analyst.html.
Shares of Horizon Pharma PLC (NASDAQ HZNP) opened at $13.57 on Friday. The company has a market cap of $2,171.49, a PE ratio of 9.60, a P/E/G ratio of 1.12 and a beta of 1.32. Horizon Pharma PLC has a fifty-two week low of $9.45 and a fifty-two week high of $21.98. The company has a current ratio of 1.64, a quick ratio of 1.46 and a debt-to-equity ratio of 1.89.
Horizon Pharma PLC (NASDAQ:HZNP) last released its quarterly earnings data on Monday, November 6th. The biopharmaceutical company reported $0.26 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.04. The firm had revenue of $271.60 million for the quarter, compared to the consensus estimate of $259.74 million. Horizon Pharma PLC had a negative net margin of 45.28% and a positive return on equity of 20.22%. The firm’s revenue was up 30.1% on a year-over-year basis. During the same quarter in the previous year, the firm earned $0.70 earnings per share.
Several large investors have recently bought and sold shares of HZNP. Bank of Montreal Can raised its position in shares of Horizon Pharma PLC by 16.3% in the second quarter. Bank of Montreal Can now owns 9,809 shares of the biopharmaceutical company’s stock valued at $116,000 after buying an additional 1,378 shares during the last quarter. Sheaff Brock Investment Advisors LLC raised its position in shares of Horizon Pharma PLC by 5.0% in the second quarter. Sheaff Brock Investment Advisors LLC now owns 10,500 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 500 shares during the last quarter. Family Management Corp acquired a new position in shares of Horizon Pharma PLC in the second quarter valued at approximately $131,000. Ballentine Partners LLC acquired a new position in shares of Horizon Pharma PLC in the second quarter valued at approximately $139,000. Finally, Teacher Retirement System of Texas raised its position in shares of Horizon Pharma PLC by 12.8% in the second quarter. Teacher Retirement System of Texas now owns 12,941 shares of the biopharmaceutical company’s stock valued at $154,000 after buying an additional 1,466 shares during the last quarter. 82.56% of the stock is owned by institutional investors and hedge funds.
About Horizon Pharma PLC
Horizon Pharma Public Limited Company is a biopharmaceutical company. The Company is focused on identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. As of December 31, 2016, the Company marketed 11 medicines through its orphan, rheumatology and primary care business units.
Receive News & Ratings for Horizon Pharma PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Horizon Pharma PLC and related companies with MarketBeat.com's FREE daily email newsletter.